A Real-world Comparative Study on the Efficacy and Safety of Inebilizumab versus Rituximab in the Treatment of Neuromyelitis Optica Spectrum Disorder (P6-1.007)

作者
Wenping Zhu,Ao Shen,Hongbo Liu
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:106 (11_Supplement_1)
标识
DOI:10.1212/wnl.0000000000216055
摘要

Objective To study and compare the efficacy and safety of inebilizumab and rituximab in the treatment of neuromyelitis optica spectrum disorder (NMOSD). Background The introduction of Monoclonal antibody is a major advance in NMOSD therapy; however, a critical gap remains in the comparative evidence regarding their efficacy and safety. Design/Methods This study was a multi-center retrospective observational study. Patients diagnosed with AQP4-IgG positive NMOSD were included, regularly treated with inebilizumab or rituximab.The main clinical outcomes included recurrence rate, ARR, EDSS, the number and range of lesions in the MRI T2FLAIR sequence, AQP4-IgG titers, B lymphocyte count and percentage. Results A total of 163 NMOSD patients were included, including inebilizumab(n=107) and rituximab(n=56) groups. The recurrence rates of patients after using inebilizumab and rituximab were 8.41% and 19.64%, and the difference was statistically significant (P<0.05). The ARR and EDSS scores of both groups decreased (P<0.05).In the Inebilizumab and rituximab groups, the number of lesions in the MRI T2FLAIR sequence decreased in 23.33% and 29.63% of the patients, and The lesion range in the MRI decreased in 93.33% and 92.59%. The percentages of B lymphocytes in the inebilizumab group at half a year and one year were 0.64±2.65(%) and 0.25±0.57(%)(P < 0.05),and in the rituximab group are 3.84±4.70(%) and 3.18±3.63(%)(P < 0.05).The difference between the two groups was statistically significant (P < 0.05). To date, there have been 5 and 7 adverse events of inelizumab and rituximab, most of which were pulmonary infections. There were no serious adverse events. Conclusions We found that both inebilizumab and rituximab could effectively reduce the ARR and EDSS of patients with NMOSD and significantly decrease the range of imaging lesions. Inebilizumab is more effective and stable in reducing the percentage and count of B cells. Compared with rituximab, patients using inebilizumab have a lower recurrence rate and cause fewer adverse events. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff . Disclosure: The institution of Dr. Zhu has received research support from China. The institution of Miss Shen has received research support from National Natural Science Foundation of China. The institution of Hongbo Liu has received research support from China.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男的应助被开朗的尔蝶采纳,获得10
刚刚
刚刚
刚刚
zxt完成签到,获得积分10
1秒前
周周完成签到,获得积分10
1秒前
bow发布了新的文献求助10
1秒前
刻苦的幻巧完成签到 ,获得积分10
2秒前
李珂完成签到,获得积分10
2秒前
小乐完成签到,获得积分10
3秒前
辛勤元芹发布了新的文献求助10
3秒前
形成发布了新的文献求助10
3秒前
5秒前
6秒前
我是老大的应助被yiyi采纳,获得10
6秒前
6秒前
科目三的应助被冰棍采纳,获得10
6秒前
7秒前
积极的鬼神完成签到 ,获得积分10
7秒前
散装洋芋发布了新的文献求助10
8秒前
NexusExplorer的应助被橙子采纳,获得10
8秒前
蜜糖果仁完成签到,获得积分10
9秒前
zyh666完成签到,获得积分10
9秒前
甜美寻双给甜美寻双的求助进行了留言
9秒前
linxi完成签到,获得积分10
9秒前
heshicong完成签到,获得积分10
10秒前
10秒前
小王院士完成签到,获得积分10
10秒前
11秒前
12秒前
12秒前
炸薯条发布了新的文献求助10
13秒前
糊涂的向秋完成签到,获得积分10
13秒前
赘婿的应助被bow采纳,获得10
13秒前
369ninja的应助被fyl采纳,获得10
14秒前
璐璐发布了新的文献求助10
14秒前
扶桑完成签到,获得积分10
15秒前
16秒前
16秒前
111完成签到,获得积分10
17秒前
风吹麦浪的应助被believe采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527